IBJNews

Court upholds Lilly patent on cancer drug Alimta

Back to TopCommentsE-mailPrintBookmark and Share

Indianapolis-based Eli Lily and Co. said a federal court judge has upheld a patent protecting one of its best-selling drugs, the cancer treatment Alimta.

A trial on the drug's compound patent, which protects its chemical makeup, started Nov. 8 and ended Monday with a ruling from the U.S. District Court for the District of Delaware, Lilly said. Generic drugmaker Teva Pharmaceuticals Industries Ltd. had challenged the patent, which protects Alimta until July 2016.

Alimita was Lilly's third-best-selling drug in the third quarter, trailing only the antipsychotic Zyprexa and the antidepressant Cymbalta. Revenue from Alimta climbed 21 percent, to $560.3 million, in the quarter, as sales in Japan rose. Alimta rang up $1.64 billion in sales during the first three quarters of 2010.

It was a welcome court win after a difficult few months for Lilly, which is facing a wave of patent expirations in coming years.

In August, a federal judge in New Jersey ruled that the company's method-of-use patent for attention deficit hyperactivity drug Strattera is invalid; Lilly is appealing that decision.  The previous month, a federal appeals court upheld a ruling that invalidated a patent on cancer drug Gemzar, which generates $750 million in U.S. sales each year.

A generic version of Gemzar launched Monday.

Gemzar is the first of several blockbuster Lilly drugs that will see their patents expire by 2013. Generic versions of Zyprexa, Cymbalta, Evista and Strattera could zap nearly half of Lilly's current sales, putting great pressure on the company to find new drugs to take their place.

Alimta is a chemotherapy drug used to treat advanced nonsquamous non-small cell lung cancer and malignant pleural mesothelioma, a cancer that affects the inside lining of the chest cavity.

Lilly said last month its third-quarter profit jumped 38 percent to $1.3 billion, as international sales climbed. But, aside from court challenges, the company also faces patent expirations for some of its key products. That includes Zyprexa next year and Cymbalta in 2013.

Analysts who follow Lilly question how it will make up for the lost revenue. Company leaders have repeatedly expressed confidence in their pipeline of drugs under development, and they also point to growth opportunities in the animal health business and emerging international markets.

 

 

 


 
 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. These liberals are out of control. They want to drive our economy into the ground and double and triple our electric bills. Sierra Club, stay out of Indy!

  2. These activist liberal judges have gotten out of control. Thankfully we have a sensible supreme court that overturns their absurd rulings!

  3. Maybe they shouldn't be throwing money at the IRL or whatever they call it now. Probably should save that money for actual operations.

  4. For you central Indiana folks that don't know what a good pizza is, Aurelio's will take care of that. There are some good pizza places in central Indiana but nothing like this!!!

  5. I am troubled with this whole string of comments as I am not sure anyone pointed out that many of the "high paying" positions have been eliminated identified by asterisks as of fiscal year 2012. That indicates to me that the hospitals are making responsible yet difficult decisions and eliminating heavy paying positions. To make this more problematic, we have created a society of "entitlement" where individuals believe they should receive free services at no cost to them. I have yet to get a house repair done at no cost nor have I taken my car that is out of warranty for repair for free repair expecting the government to pay for it even though it is the second largest investment one makes in their life besides purchasing a home. Yet, we continue to hear verbal and aggressive abuse from the consumer who expects free services and have to reward them as a result of HCAHPS surveys which we have no influence over as it is 3rd party required by CMS. Peel the onion and get to the root of the problem...you will find that society has created the problem and our current political landscape and not the people who were fortunate to lead healthcare in the right direction before becoming distorted. As a side note, I had a friend sit in an ED in Canada for nearly two days prior to being evaluated and then finally...3 months later got a CT of the head. You pay for what you get...

ADVERTISEMENT